-
1
-
-
15744373791
-
-
Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, eds. World Health Organization Classification of Tumours 7. Lyon, France: IARC Press
-
Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, eds. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. World Health Organization Classification of Tumours 7. Lyon, France: IARC Press; 2004.
-
(2004)
Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart
-
-
-
2
-
-
62249156223
-
Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib
-
Zakowski MF, Hussain S, Pao W, et al. Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib. Arch Pathol Lab Med 2009;133:470-477
-
(2009)
Arch Pathol Lab Med
, vol.133
, pp. 470-477
-
-
Zakowski, M.F.1
Hussain, S.2
Pao, W.3
-
3
-
-
15744372810
-
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
-
Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:e17.
-
(2005)
PLoS Med
, vol.2
-
-
Pao, W.1
Wang, T.Y.2
Riely, G.J.3
-
4
-
-
52049090365
-
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21
-
Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008;26:4268-4275
-
(2008)
J Clin Oncol
, vol.26
, pp. 4268-4275
-
-
Zhu, C.Q.1
Da Cunha Santos, G.2
Ding, K.3
-
6
-
-
40049100818
-
Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma
-
DOI 10.1097/JTO.0b013e318160c607, PII 0124389420080200000004
-
Marks JL, Broderick S, Zhu Q, et al. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol 2008;3:111-116 (Pubitemid 351323183)
-
(2008)
Journal of Thoracic Oncology
, vol.3
, Issue.2
, pp. 111-116
-
-
Marks, J.L.1
Broderick, S.2
Zhou, Q.3
Chitale, D.4
Li, A.R.5
Zakowski, M.F.6
Kris, M.G.7
Rusch, V.W.8
Azzoli, C.G.9
Seshan, V.E.10
Ladanyi, M.11
Pao, W.12
-
7
-
-
36749103137
-
Auf dem Weg zu einer individualisierten Therapie des nicht-kleinzelligen Bronchialkarzinoms (NSCLC) - Stellenwert molekularer pradiktions- und prognosefaktoren
-
DOI 10.1055/s-2007-980130
-
Zirlik S, Lampert S, Hahn EG, Wiest GH, Bruckl WM. An approach to individualized therapy of non-small cell lung carcinoma (NSCLC) - relevance of molecular predictive and prognostic factors [German]. Pneumologie 2007;61:731-738 (Pubitemid 350214159)
-
(2007)
Pneumologie
, vol.61
, Issue.11
, pp. 731-740
-
-
Zirlik, S.1
Lampert, S.2
Hahn, E.G.3
Wiest, G.H.4
Bruckl, W.M.5
-
8
-
-
34250843259
-
Weighing tumor biology in treatment decisions for patients with non-small cell lung cancer
-
DOI 10.1097/01.JTO.0000269737.05962.a0, PII 0124389420070600200004
-
Shepherd FA, Rosell R. Weighing tumor biology in treatment decisions for patients with non-small cell lung cancer. J Thorac Oncol 2007;2(suppl 2):S68-76. (Pubitemid 46988096)
-
(2007)
Journal of Thoracic Oncology
, vol.2
, Issue.SUPPL. 2
-
-
Shepherd, F.A.1
Rosell, R.2
-
9
-
-
63349108087
-
Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients
-
Leary AF, Hanna WM, van de Vijver MJ, et al. Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients. J Clin Oncol 2009;27:1694-1705
-
(2009)
J Clin Oncol
, vol.27
, pp. 1694-1705
-
-
Leary, A.F.1
Hanna, W.M.2
Van De Vijver, M.J.3
-
10
-
-
0036729263
-
Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: A phase III randomized trial
-
DOI 10.1200/JCO.2002.12.112
-
Kosmidis P, Mylonakis N, Nicolaides C, et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 2002;20:3578-3585 (Pubitemid 34983216)
-
(2002)
Journal of Clinical Oncology
, vol.20
, Issue.17
, pp. 3578-3585
-
-
Kosmidis, P.1
Mylonakis, N.2
Nicolaides, C.3
Kalophonos, C.4
Samantas, E.5
Boukovinas, J.6
Fountzilas, G.7
Skarlos, D.8
Economopoulos, T.9
Tsavdaridis, D.10
Papakostas, P.11
Bacoyiannis, C.12
Dimopoulos, M.13
-
11
-
-
0037050352
-
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
-
DOI 10.1056/NEJMoa011954
-
Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98 (Pubitemid 34438899)
-
(2002)
New England Journal of Medicine
, vol.346
, Issue.2
, pp. 92-98
-
-
Schiller, J.H.1
Harrington, D.2
Belani, C.P.3
Langer, C.4
Sandler, A.5
Krook, J.6
Zhu, J.7
Johnson, D.H.8
-
12
-
-
0042413836
-
Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 Study Group
-
DOI 10.1200/JCO.2003.12.046
-
Fossella F, Pereira JR, von Pawel J, et al. Randomized multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the tax 326 study group. J Clin Oncol 2003;21:3016-3024 (Pubitemid 46606280)
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.16
, pp. 3016-3024
-
-
Fossella, F.1
Pereira, J.R.2
Von Pawel, J.3
Pluzanska, A.4
Gorbounova, V.5
Kaukel, E.6
Mattson, K.V.7
Ramlau, R.8
Szczesna, A.9
Fidias, P.10
Millward, M.11
Belani, C.P.12
-
13
-
-
21144437547
-
Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: A phase III randomized trial
-
DOI 10.1200/JCO.2005.04.016
-
Georgoulias V, Ardavanis A, Tsiafaki X, et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-call lung cancer: a phase III randomized trial. J Clin Oncol 2005;23:2937-2945 (Pubitemid 46224112)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.13
, pp. 2937-2945
-
-
Georgoulias, V.1
Ardavanis, A.2
Tsiafaki, X.3
Agelidou, A.4
Mixalopoulou, P.5
Anagnostopoulou, O.6
Ziotopoulos, P.7
Toubis, M.8
Syrigos, K.9
Samaras, N.10
Polyzos, A.11
Christou, A.12
Kakolyris, S.13
Kouroussis, C.14
Androulakis, N.15
Samonis, G.16
Chatzidaki, D.17
-
14
-
-
37349108995
-
Pemetrexed + carboplatin versus gemcitabine + carboplatin in the treatment of stage IIIB/IV non-small cell lung cancer
-
abstract 7517. Available online at: cited June 26, 2009
-
Grønberg BH, Bremnes R, Aasebø U, et al. Pemetrexed + carboplatin versus gemcitabine + carboplatin in the treatment of stage IIIB/IV non-small cell lung cancer [abstract 7517]. Proc Am Soc Clin Oncol 2007;25:. [Available online at: www.asco. org/ASCOv2/Meetings/Abstracts?&vmview=abst- detail-view &confID=47&abstractID=31787; cited June 26, 2009]
-
(2007)
Proc Am Soc Clin Oncol
, vol.25
-
-
Grønberg, B.H.1
Bremnes, R.2
Aasebø, U.3
-
15
-
-
49049089802
-
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer
-
Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26:3543-3551
-
(2008)
J Clin Oncol
, vol.26
, pp. 3543-3551
-
-
Scagliotti, G.V.1
Parikh, P.2
Von Pawel, J.3
-
16
-
-
24944497744
-
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib
-
Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-5909
-
(2005)
J Clin Oncol
, vol.23
, pp. 5900-5909
-
-
Eberhard, D.A.1
Johnson, B.E.2
Amler, L.C.3
-
17
-
-
45149102984
-
Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023
-
Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008;26:2450-2456
-
(2008)
J Clin Oncol
, vol.26
, pp. 2450-2456
-
-
Kelly, K.1
Chansky, K.2
Gaspar, L.E.3
-
18
-
-
52749099497
-
Assessment of somatic K-ras mutations as a mechanism associated with resistance to EGFR-targeted agents: A systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
-
Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic K-ras mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008;9:962-972
-
(2008)
Lancet Oncol
, vol.9
, pp. 962-972
-
-
Linardou, H.1
Dahabreh, I.J.2
Kanaloupiti, D.3
-
19
-
-
0035883542
-
Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung
-
DOI 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H
-
Ahrendt SA, Decker PA, Alawi EA, et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 2001; 92:1525-1530 (Pubitemid 32947838)
-
(2001)
Cancer
, vol.92
, Issue.6
, pp. 1525-1530
-
-
Ahrendt, S.A.1
Anthony Decker, P.2
Alawi, E.A.3
Zhu, Y.-R.4
Sanchez-Cespedes, M.5
Yang, S.C.6
Haasler, G.B.7
Kajdacsy-Balla, A.8
Demeure, M.J.9
Sidransky, D.10
-
20
-
-
0028843552
-
Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
-
Non-Small Cell Lung Cancer Collaborative Group
-
Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995;311:899-909.
-
(1995)
Br Med J
, vol.311
, pp. 899-909
-
-
-
21
-
-
0022646219
-
Long-term survivors in metastatic non-small-cell lung cancer: An Eastern Cooperative Oncology Group study
-
Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1986; 4:702-709 (Pubitemid 16114717)
-
(1986)
Journal of Clinical Oncology
, vol.4
, Issue.5
, pp. 702-709
-
-
Finkelstein, D.M.1
Ettinger, D.S.2
Ruckdeschel, J.C.3
-
22
-
-
0033950286
-
Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial
-
Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000;18:623-631
-
(2000)
J Clin Oncol
, vol.18
, pp. 623-631
-
-
Bonomi, P.1
Kim, K.2
Fairclough, D.3
-
23
-
-
25444511051
-
Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer
-
DOI 10.1093/annonc/mdi216
-
Belani CP, Lee JS, Socinski MA, et al. Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol 2005;16:1069-1075 (Pubitemid 41418307)
-
(2005)
Annals of Oncology
, vol.16
, Issue.7
, pp. 1069-1075
-
-
Belani, C.P.1
Lee, J.S.2
Socinski, M.A.3
Robert, F.4
Waterhouse, D.5
Rowland, K.6
Ansari, R.7
Lilenbaum, R.8
Natale, R.B.9
-
24
-
-
0035397994
-
Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial
-
Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19:3210-3218 (Pubitemid 32591438)
-
(2001)
Journal of Clinical Oncology
, vol.19
, Issue.13
, pp. 3210-3218
-
-
Kelly, K.1
Crowley, J.2
Bunn Jr., P.A.3
Presant, C.A.4
Grevstad, P.K.5
Moinpour, C.M.6
Ramsey, S.D.7
Wozniak, A.J.8
Weiss, G.R.9
Moore, D.F.10
Israel, V.K.11
Livingston, R.B.12
Gandara, D.R.13
-
25
-
-
0036843105
-
Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer
-
DOI 10.1200/JCO.2002.02.068
-
Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285-4291 (Pubitemid 35266288)
-
(2002)
Journal of Clinical Oncology
, vol.20
, Issue.21
, pp. 4285-4291
-
-
Scagliotti, G.V.1
De Marinis, F.2
Rinaldi, M.3
Crino, L.4
Gridelli, C.5
Ricci, S.6
Matano, E.7
Boni, C.8
Marangolo, M.9
Failla, G.10
Altavilla, G.11
Adamo, V.12
Ceribelli, A.13
Clerici, M.14
Di Costanzo, F.15
Frontini, L.16
Tonato, M.17
-
26
-
-
33144474858
-
Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? a meta-analysis of phase III randomized trials
-
DOI 10.1016/j.lungcan.2005.11.001, PII S0169500205005830
-
Pujol JL, Barlesi F, Daurès JP. Should chemotherapy combinations for advanced non-small cell lung cancer be platinumbased? A meta-analysis of phase III randomized trials. Lung Cancer 2006;51:335-345 (Pubitemid 43265817)
-
(2006)
Lung Cancer
, vol.51
, Issue.3
, pp. 335-345
-
-
Pujol, J.-L.1
Barlesi, F.2
Daures, J.-P.3
-
27
-
-
10444237218
-
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: A meta-analysis of survival outcomes
-
Le Chevalier T, Scagliotti G, Natale R, et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 2005;47:69-80.
-
(2005)
Lung Cancer
, vol.47
, pp. 69-80
-
-
Le Chevalier, T.1
Scagliotti, G.2
Natale, R.3
-
28
-
-
34848818029
-
Comparison of docetaxel- And vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: A meta-analysis of seven randomized clinical trials
-
DOI 10.1097/JTO.0b013e318153fa2b, PII 0124389420071000000011
-
Douillard JY, Laporte S, Fossella F, et al. Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials. J Thorac Oncol 2007;2:939-946 (Pubitemid 47511598)
-
(2007)
Journal of Thoracic Oncology
, vol.2
, Issue.10
, pp. 939-946
-
-
Douillard, J.-Y.1
Laporte, S.2
Fossella, F.3
Georgoulias, V.4
Pujol, J.-L.5
Kubota, K.6
Monnier, A.7
Kudoh, S.8
Rubio, J.E.9
Cucherat, M.10
-
29
-
-
44949218458
-
Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease
-
CD004569
-
Delbaldo C, Michiels S, Rolland E, et al. Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease. Cochrane Database Syst Rev 2007;(4):CD004569.
-
(2007)
Cochrane Database Syst Rev
, Issue.4
-
-
Delbaldo, C.1
Michiels, S.2
Rolland, E.3
-
30
-
-
34347379142
-
Cisplatin- versus carboplatin- based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data metaanalysis
-
Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- versus carboplatin- based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data metaanalysis. J Natl Cancer Inst 2007;99:847-857
-
(2007)
J Natl Cancer Inst
, vol.99
, pp. 847-857
-
-
Ardizzoni, A.1
Boni, L.2
Tiseo, M.3
-
31
-
-
60149111149
-
Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: A systematic review with meta-analysis
-
Lima JP, dos Santos LV, Sasse EC, Sasse AD. Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: a systematic review with meta-analysis. Eur J Cancer 2009;45:601-607
-
(2009)
Eur J Cancer
, vol.45
, pp. 601-607
-
-
Lima, J.P.1
Dos Santos, L.V.2
Sasse, E.C.3
Sasse, A.D.4
-
32
-
-
0035281498
-
Duration of chemotherapy in advanced non-small-cell lung cancer: A randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin
-
Smith IE, O'Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001;19:1336-1343
-
(2001)
J Clin Oncol
, vol.19
, pp. 1336-1343
-
-
Smith, I.E.1
O'Brien, M.E.2
Talbot, D.C.3
-
33
-
-
0036499649
-
Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer
-
DOI 10.1200/JCO.20.5.1335
-
Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2002;20:1335-1343 (Pubitemid 34182817)
-
(2002)
Journal of Clinical Oncology
, vol.20
, Issue.5
, pp. 1335-1343
-
-
Socinski, M.A.1
Schell, M.J.2
Peterman, A.3
Bakri, K.4
Yates, S.5
Gitten, R.6
Unger, P.7
Lee, J.8
Lee, J.-H.9
Tynan, M.10
Moore, M.11
Kies, M.S.12
-
34
-
-
0034069620
-
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum- Based chemotherapy
-
Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103 (Pubitemid 30324363)
-
(2000)
Journal of Clinical Oncology
, vol.18
, Issue.10
, pp. 2095-2103
-
-
Shepherd, F.A.1
Dancey, J.2
Ramlau, R.3
Mattson, K.4
Gralla, R.5
O'Rourke, M.6
Levitan, N.7
Gressot, L.8
Vincent, M.9
Burkes, R.10
Coughlin, S.11
Kim, Y.12
Berille, J.13
-
35
-
-
2442661845
-
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
-
Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597
-
(2004)
J Clin Oncol
, vol.22
, pp. 1589-1597
-
-
Hanna, N.1
Shepherd, F.A.2
Fossella, F.V.3
-
36
-
-
64049105491
-
Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC)
-
Peterson P, Park K, Fossella F, Gatzemeier U, John W, Scagliotti G. Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2007;2(suppl 4):S316-17.
-
(2007)
J Thorac Oncol
, vol.2
, Issue.SUPPL. 4
-
-
Peterson, P.1
Park, K.2
Fossella, F.3
Gatzemeier, U.4
John, W.5
Scagliotti, G.6
-
37
-
-
64049115311
-
The differential efficacy of pemetrexed according to NSCLC histology: A review of two phase III studies
-
Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009;14:253-263
-
(2009)
Oncologist
, vol.14
, pp. 253-263
-
-
Scagliotti, G.1
Hanna, N.2
Fossella, F.3
-
38
-
-
33749077728
-
Elderly patients benefit from second-line cytotoxic chemotherapy: A subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer
-
DOI 10.1200/JCO.2006.06.7835
-
Weiss GJ, Langer C, Rosell R, et al. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small- cell lung cancer. J Clin Oncol 2006;24:4405-4413 (Pubitemid 46630978)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.27
, pp. 4405-4411
-
-
Weiss, G.J.1
Langer, C.2
Rosell, R.3
Hanna, N.4
Shepherd, F.5
Einhorn, L.H.6
Nguyen, B.7
Paul, S.8
McAndrews, P.9
Bunn Jr., P.A.10
Kelly, K.11
-
39
-
-
37549036328
-
Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: An analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer
-
de Marinis F, Pereira JR, Fossella F, et al. Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer. J Thorac Oncol 2008;3:30-36
-
(2008)
J Thorac Oncol
, vol.3
, pp. 30-36
-
-
De Marinis, F.1
Pereira, J.R.2
Fossella, F.3
-
40
-
-
22044445517
-
Erlotinib in previously treated non-small-cell lung cancer
-
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132
-
(2005)
N Engl J Med
, vol.353
, pp. 123-132
-
-
Shepherd, F.A.1
Rodrigues Pereira, J.2
Ciuleanu, T.3
-
41
-
-
22044453790
-
Erlotinib in lung cancer - Molecular and clinical predictors of outcome
-
Erratum in: N Engl J Med 2006;355:1746
-
Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-44. [Erratum in: N Engl J Med 2006;355:1746]
-
(2005)
N Engl J Med
, vol.353
, pp. 133-144
-
-
Tsao, M.S.1
Sakurada, A.2
Cutz, J.C.3
-
42
-
-
33745928129
-
Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group Study br.21
-
Clark GM, Zborowski DM, Santabarbara P, et al. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer 2006;7:389-394 (Pubitemid 44043548)
-
(2006)
Clinical Lung Cancer
, vol.7
, Issue.6
, pp. 389-394
-
-
Clark, G.M.1
Zborowski, D.M.2
Santabarbara, P.3
Ding, K.4
Whitehead, M.5
Seymour, L.6
Shepherd, F.A.7
-
43
-
-
27544503230
-
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
-
DOI 10.1016/S0140-6736(05)67625-8, PII S0140673605676258
-
Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-1537 (Pubitemid 41540110)
-
(2005)
Lancet
, vol.366
, Issue.9496
, pp. 1527-1537
-
-
Thatcher, N.1
Chang, A.2
Parikh, P.3
Pereira, J.R.4
Ciuleanu, T.5
Von Pawel, J.6
Thongprasert, S.7
Tan, E.H.8
Pemberton, K.9
Archer, V.10
Carroll, K.11
-
44
-
-
56249109644
-
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial
-
Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372:1809-1818
-
(2008)
Lancet
, vol.372
, pp. 1809-1818
-
-
Kim, E.S.1
Hirsh, V.2
Mok, T.3
-
45
-
-
59749100191
-
Phase III, randomized, open-label, first-line study of gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients (Pts) with advanced non-small-cell lung cancer (NSCLC) (IPASS)
-
abstract LBA2
-
Mok T, Wu YL, Thongprasert S, et al. Phase III, randomized, open-label, first-line study of gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients (Pts) with advanced non-small-cell lung cancer (NSCLC) (IPASS) [abstract LBA2]. Ann Oncol 2008;19(suppl 8): viii1-viii4.
-
(2008)
Ann Oncol
, vol.19
, Issue.SUPPL. 8
-
-
Mok, T.1
Wu, Y.L.2
Thongprasert, S.3
-
46
-
-
62449124416
-
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL
-
Erratum in: J Clin Oncol 2009;27:2415
-
Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009;27:1227-34. [Erratum in: J Clin Oncol 2009;27:2415]
-
(2009)
J Clin Oncol
, vol.27
, pp. 1227-1234
-
-
Reck, M.1
Von Pawel, J.2
Zatloukal, P.3
-
47
-
-
33845490014
-
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
-
DOI 10.1056/NEJMoa061884
-
Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50. [Erratum in: N Engl J Med 2007;356:318] (Pubitemid 44917502)
-
(2006)
New England Journal of Medicine
, vol.355
, Issue.24
, pp. 2542-2550
-
-
Sandler, A.1
Gray, R.2
Perry, M.C.3
Brahmer, J.4
Schiller, J.H.5
Dowlati, A.6
Lilenbaum, R.7
Johnson, D.H.8
-
48
-
-
65349091355
-
Randomized phase ii and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer
-
Smit EF, Burgers SA, Biesma B, et al. Randomized phase ii and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 2009;27:2038-2045
-
(2009)
J Clin Oncol
, vol.27
, pp. 2038-2045
-
-
Smit, E.F.1
Burgers, S.A.2
Biesma, B.3
-
49
-
-
0023851771
-
First-line chemotherapy rechallenge after relapse in small cell lung cancer
-
Vincent M, Evans B, Smith I. First-line chemotherapy rechallenge after relapse in small cell lung cancer. Cancer Chemother Pharmacol 1988;21:45-48 (Pubitemid 18050480)
-
(1988)
Cancer Chemotherapy and Pharmacology
, vol.21
, Issue.1
, pp. 45-48
-
-
Vincent, M.1
Evans, B.2
Smith, I.3
-
50
-
-
67650281462
-
Phase III study by the Norwegian Lung Cancer Study Group: Pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer
-
Epub ahead of print
-
Grønberg BH, Bremnes RM, Fløtten O, et al. Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009;[Epub ahead of print].
-
(2009)
J Clin Oncol
-
-
Grønberg, B.H.1
Bremnes, R.M.2
Fløtten, O.3
-
51
-
-
51349109631
-
FLEX: A randomized, multicenter, phase II study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)
-
abstract 3. Available online at: cited June 26, 2009
-
Pirker R, Szczesna A, von Pawel J, et al. FLEX: a randomized, multicenter, phase II study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) [abstract 3]. Proc Am Soc Clin Oncol 2008:26:6S. [Available online at: www.asco.org/ASCOv2/Meetings/ Abstracts?&vmview=abst-detail-view&confID=55&abstractID=30338; cited June 26, 2009]
-
(2008)
Proc Am Soc Clin Oncol
, vol.26
-
-
Pirker, R.1
Szczesna, A.2
Von Pawel, J.3
-
52
-
-
20044364940
-
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
-
DOI 10.1093/jnci/dji055
-
Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-346 (Pubitemid 40425952)
-
(2005)
Journal of the National Cancer Institute
, vol.97
, Issue.5
, pp. 339-346
-
-
Shigematsu, H.1
Lin, L.2
Takahashi, T.3
Nomura, M.4
Suzuki, M.5
Wistuba, I.I.6
Fong, K.M.7
Lee, H.8
Toyooka, S.9
Shimizu, N.10
Fujisawa, T.11
Feng, Z.12
Roth, J.A.13
Herz, J.14
Minna, J.D.15
Gazdar, A.F.16
-
53
-
-
0035281498
-
Duration of chemotherapy in advanced non-small-cell lung cancer: A randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin
-
Smith IE, O'Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001;19:1336-1343
-
(2001)
J Clin Oncol
, vol.19
, pp. 1336-1343
-
-
Smith, I.E.1
O'Brien, M.E.2
Talbot, D.C.3
-
54
-
-
0036499649
-
Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer
-
DOI 10.1200/JCO.20.5.1335
-
Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage iiib/iv non-small- cell lung cancer. J Clin Oncol 2002;20:1335-1343 (Pubitemid 34182817)
-
(2002)
Journal of Clinical Oncology
, vol.20
, Issue.5
, pp. 1335-1343
-
-
Socinski, M.A.1
Schell, M.J.2
Peterman, A.3
Bakri, K.4
Yates, S.5
Gitten, R.6
Unger, P.7
Lee, J.8
Lee, J.-H.9
Tynan, M.10
Moore, M.11
Kies, M.S.12
-
55
-
-
15944388587
-
Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer
-
DOI 10.1093/jnci/dji096
-
Westeel V, Quoix E, Moro-Sibilot D, et al. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst 2005;97:499-506. (Pubitemid 40590431)
-
(2005)
Journal of the National Cancer Institute
, vol.97
, Issue.7
, pp. 499-506
-
-
Westeel, V.1
Quoix, E.2
Moro-Sibilot, D.3
Mercier, M.4
Breton, J.-L.5
Debieuvre, D.6
Richard, P.7
Haller, M.-A.8
Milleron, B.9
Herman, D.10
Level, M.-C.11
Lebas, F.-X.12
Puyraveau, M.13
Depierre, A.14
-
56
-
-
33750207905
-
Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer
-
DOI 10.1038/sj.bjc.6603383, PII 6603383
-
von Plessen C, Bergman B, Andresen O, et al. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer 2006;95:966-973 (Pubitemid 44606820)
-
(2006)
British Journal of Cancer
, vol.95
, Issue.8
, pp. 966-973
-
-
Von Plessen, C.1
Bergman, B.2
Andresen, O.3
Bremnes, R.M.4
Sundstrom, S.5
Gilleryd, M.6
Stephens, R.7
Vilsvik, J.8
Aasebo, U.9
Sorenson, S.10
-
57
-
-
33646485007
-
Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial
-
Brodowicz T, Krzakowski M, Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006;52:155-163
-
(2006)
Lung Cancer
, vol.52
, pp. 155-163
-
-
Brodowicz, T.1
Krzakowski, M.2
Zwitter, M.3
-
58
-
-
59149092945
-
Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer
-
Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:591-598
-
(2009)
J Clin Oncol
, vol.27
, pp. 591-598
-
-
Fidias, P.M.1
Dakhil, S.R.2
Lyss, A.P.3
-
59
-
-
70349092474
-
Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC)
-
abstract CRA8000. Available online at: cited June 26, 2009
-
Belani CP, Brodowicz T, Ciuleanu T, et al. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: a randomized phase III study in advanced non-small cell lung cancer (NSCLC) [abstract CRA8000]. Proc Am Soc Clin Oncol 2009;27:. [Available online at: www.asco.org/ ASCOv2/Meetings/Abstracts?&vmview=abst-detail-view& confID= 65&abstractID=33019; cited June 26, 2009]
-
(2009)
Proc Am Soc Clin Oncol
, vol.27
-
-
Belani, C.P.1
Brodowicz, T.2
Ciuleanu, T.3
-
60
-
-
70349475409
-
SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC
-
abstract 8001. Available online at: cited June 26, 2009
-
Cappuzzo F, Ciuleanu T, Stelmakh L, et al. SATURN: a double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC [abstract 8001]. Proc Am Soc Clin Oncol 2009;27:. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst-detail- view&confID=65&abstractID=32756; cited June 26, 2009]
-
(2009)
Proc Am Soc Clin Oncol
, vol.27
-
-
Cappuzzo, F.1
Ciuleanu, T.2
Stelmakh, L.3
-
61
-
-
70349476965
-
Biomarker analyses from the phase III placebo-controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC
-
abstract 8020. Available online at: cited June 26, 2009
-
Brugger W, Triller N, Blasinska-Morawiec M, et al. Biomarker analyses from the phase III placebo-controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC [abstract 8020]. Proc Am Soc Clin Oncol 2009;27:. [Available online at: www.asco.org/ASCOv2/ Meetings/Abstracts?&vmview=abst-detail-view&confID= 65&abstractID= 32849; cited June 26, 2009]
-
(2009)
Proc Am Soc Clin Oncol
, vol.27
-
-
Brugger, W.1
Triller, N.2
Blasinska-Morawiec, M.3
-
62
-
-
70349477817
-
A randomized, double-blind, placebo-controlled, phase IIIB trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC)
-
on behalf of the ATLAS Investigators. abstract LBA8002. Available online at: cited June 26, 2009
-
Miller VA, O'Connor P, Soh C, Kabbinavar F, on behalf of the ATLAS Investigators. A randomized, double-blind, placebo-controlled, phase IIIB trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) [abstract LBA8002]. Proc Am Soc Clin Oncol 2009;27:. [Available online at: www.asco.org/ASCOv2/ Meetings/ Abstracts?&vmview=abst-detail-view&confID=65&abstract ID=30819; cited June 26, 2009]
-
(2009)
Proc Am Soc Clin Oncol
, vol.27
-
-
Miller, V.A.1
O'Connor, P.2
Soh, C.3
Kabbinavar, F.4
-
63
-
-
70350609719
-
Cisplatin in non-small cell lung cancer (NSCLC) - Reducing the most prominent toxicity, emesis: Results of a meta-analysis with 1527 patients in randomized clinical trials (RCTS) testing the addition of an NK1 antagonist
-
abstract 8064. Available online at: cited June 26, 2009
-
Gralla RJ, Raftopoulos H, Bria E, Hesketh PJ. Cisplatin in non-small cell lung cancer (NSCLC) - reducing the most prominent toxicity, emesis: results of a meta-analysis with 1527 patients in randomized clinical trials (RCTS) testing the addition of an NK1 antagonist [abstract 8064]. Proc Am Soc Clin Oncol 2008;26:. [Available online at: www.asco.org/ASCOv2/Meetings/ Abstracts?&vmview=abst-detail-view&confID=55&abstract ID=34689; cited June 26, 2009]
-
(2008)
Proc Am Soc Clin Oncol
, vol.26
-
-
Gralla, R.J.1
Raftopoulos, H.2
Bria, E.3
Hesketh, P.J.4
-
64
-
-
43249128301
-
Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity
-
DOI 10.1097/JTO.0b013e3181651c0e, PII 0124389420080300000006
-
Hirsh V, Major PP, Lipton A, et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 2008;3:228-236 (Pubitemid 351654321)
-
(2008)
Journal of Thoracic Oncology
, vol.3
, Issue.3
, pp. 228-236
-
-
Hirsh, V.1
Major, P.P.2
Lipton, A.3
Cook, R.J.4
Langer, C.J.5
Smith, M.R.6
Brown, J.E.7
Coleman, R.E.8
-
65
-
-
0036898599
-
Subsets more likely to benefit from surgery or prophylactic cranial irradiation after chemoradiation for localized non-small-cell lung cancer
-
DOI 10.1097/00000421-200212000-00011
-
Keith B, Vincent M, Stitt L, et al. Subsets more likely to benefit from surgery or prophylactic cranial irradiation after chemoradiation for localized non-small-cell lung cancer. Am J Clin Oncol 2002;25:583-587 (Pubitemid 35453665)
-
(2002)
American Journal of Clinical Oncology: Cancer Clinical Trials
, vol.25
, Issue.6
, pp. 583-587
-
-
Keith, B.1
Vincent, M.2
Stitt, L.3
Tomiak, A.4
Malthaner, R.5
Yu, E.6
Truong, P.7
Inculet, R.8
Lefcoe, M.9
Rashid Dar, A.10
Kocha, W.11
Craig, I.12
-
66
-
-
34547937885
-
Prophylactic cranial irradiation in extensive small-cell lung cancer
-
DOI 10.1056/NEJMoa071780
-
Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007;357:664-672 (Pubitemid 47267236)
-
(2007)
New England Journal of Medicine
, vol.357
, Issue.7
, pp. 664-672
-
-
Slotman, B.1
Faivre-Finn, C.2
Kramer, G.3
Rankin, E.4
Snee, M.5
Hatton, M.6
Postmus, P.7
Collette, L.8
Musat, E.9
Senan, S.10
-
67
-
-
52949124117
-
Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: A Cochrane systematic review
-
Akl EA, van Doormaal FF, Barba M, et al. Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review. J Exp Clin Cancer Res 2008;27:4.
-
(2008)
J Exp Clin Cancer Res
, vol.27
, pp. 4
-
-
Akl, E.A.1
Van Doormaal, F.F.2
Barba, M.3
-
68
-
-
53249145767
-
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma
-
Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008;14:5731-5734
-
(2008)
Clin Cancer Res
, vol.14
, pp. 5731-5734
-
-
Riely, G.J.1
Kris, M.G.2
Rosenbaum, D.3
-
69
-
-
62449241907
-
Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers
-
Hughes AN, O'Brien ME, Petty WJ, et al. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol 2009;27:1220-1226
-
(2009)
J Clin Oncol
, vol.27
, pp. 1220-1226
-
-
Hughes, A.N.1
O'Brien, M.E.2
Petty, W.J.3
|